NCT07853378Not yet recruiting
Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia Gravis
Incidence and Predictors of Early Clinical Relapse Within Six Months After Thymectomy in Patients With Myasthenia Gravis: An Observational Longitudinal Study
Source: ClinicalTrials.gov · Last updated 1 Oct 2026
Brief summary (registry, in English)
Myasthenia gravis is an autoimmune disorder affecting neuromuscular transmission, characterized by fluctuating muscle weakness and fatigue. Surgical removal of the thymus gland (thymectomy) is an established treatment to help achieve disease control in eligible patients. However, surgery does not guarantee permanent remission, and some individuals experience disease recurrence or clinical worsening. The main objective of this observational study is to determine the incidence and clinical predictors of early relapse occurring within the first six months following thymectomy. The study evaluates adult patients with confirmed autoimmune myasthenia gravis who underwent thymectomy at Assiut University Hospitals. Patient characteristics, antibody profiles, pre-surgical disease severity, and postoperative follow-up assessments at 1, 3, and 6 months will be analyzed to identify factors associated with early clinical relapse.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 26 Sept 2026
- Start date
- Oct 2026
- Primary completion date
- Oct 2027
- Lead sponsor
- Assiut University
- Diseases
- Myasthenia gravis
- NCT number
- NCT07853378
What you commit to
- Study type: Observational
- Planned participants: 30
- From Oct 2026 to the primary completion date, Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Congenital myasthenic syndromes
- Major comorbid neurological disease making myasthenia gravis activity assessment unreliable
Other
- Insufficient or unreliable medical records
- Absence of reliable postoperative clinical assessment
- Thymectomy performed for an unrelated indication without documented myasthenia gravis
Who the study is looking for
- Age 18 years or older at the time of thymectomy
- Definite autoimmune myasthenia gravis based on compatible clinical findings with supporting electrophysiological and/or serological evidence
- History of thymectomy
- Adequate preoperative medical records
- Documented postoperative assessment sufficient to determine six-month outcome, unless a qualifying relapse or death occurs earlier
Age in the registry: 18 years to - · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.